Nivolumab
Nivolumab (brand name Opdivo) is an immune checkpoint inhibitor that blocks the PD-1 protein on T cells, allowing the immune system to recognize and attack cancer cells. In combination with ipilimumab, it is FDA-approved as a first-line treatment for unresectable malignant pleural mesothelioma.
The FDA approved nivolumab plus ipilimumab for mesothelioma in October 2020 based on the CheckMate 743 trial, which enrolled 605 patients and demonstrated improved overall survival compared to standard pemetrexed-cisplatin chemotherapy. The benefit was particularly striking in sarcomatoid mesothelioma patients, who historically had the worst outcomes with chemotherapy.
Nivolumab works by blocking PD-1, a "checkpoint" protein that cancer cells exploit to evade immune detection. Ipilimumab blocks a second checkpoint (CTLA-4). Together, they release the brakes on the immune system from two different angles, producing a more robust anti-tumor response than either drug alone.
Side effects of immunotherapy differ from chemotherapy and can include immune-mediated reactions affecting the skin, liver, lungs, thyroid, and other organs. While most side effects are manageable with corticosteroids, patients require regular monitoring. Ongoing clinical trials are evaluating nivolumab in combination with other agents and in earlier-stage disease settings.
- Also known as
- Opdivo, Anti-PD-1
- Category
- Treatment
- Related terms
- Immunotherapy, Chemotherapy, Sarcomatoid Mesothelioma, Clinical Trial, Mesothelioma
How does nivolumab work for mesothelioma?
Nivolumab blocks the PD-1 checkpoint protein on T cells, preventing cancer cells from evading immune detection and allowing the immune system to attack the tumor.
Is nivolumab FDA-approved for mesothelioma?
Yes. Nivolumab combined with ipilimumab was FDA-approved in October 2020 as a first-line treatment for unresectable malignant pleural mesothelioma.
Have questions about Nivolumab? Our attorneys can explain how this applies to your situation — at no cost.